Here, we will (i) summarize key findings linking TNF to the promotion or inhibition of tumor progression, (ii) attempt to reconcile some of the contradictory findings, and (iii) describe the scientific rationale for improving the efficacy of immune checkpoint inhibitors via TNF blockade in metastatic melanoma patients. The gene discussed is TNF; the disease is metastatic melanoma.